CoChat

ALK1-Fc Inhibits Multiple Mediators of Angiogenesis and Suppresses Tumor Growth

Open access
Mitchell, Dianne, Pobre, Eileen G., Mulivor, Aaron W., Grinberg, Asya V., Castonguay, Roselyne, Monnell, Travis E., Solban, Nicolas, Ucran, Jeffrey A., Pearsall, R. Scott, Underwood, Kathryn W., Seehra, Jasbir, Kumar, Ravindra · 2010 · Molecular Cancer Therapeutics
Cited by 155

The DOI matches its Crossref record.

Abstract

Activin receptor–like kinase-1 (ALK1) is a type I, endothelial cell–specific member of the transforming growth factor-β superfamily of receptors known to play an essential role in modulating angiogenesis and vessel maintenance. In the present study, we sought to examine the angiogenic and tumorigenic effects mediated upon the inhibition of ALK1 signaling using a soluble chimeric protein (ALK1-Fc). Of 29 transforming growth factor-β–related ligands screened by surface plasmon resonance, only bone morphogenetic protein (BMP9) and BMP10 displayed high-affinity binding to ALK1-Fc. In cell-based assays, ALK1-Fc inhibited BMP9-mediated Id-1 expression in human umbilical vein endothelial cells and inhibited cord formation by these cells on a Matrigel substrate. In a chick chorioallantoic membrane assay, ALK1-Fc reduced vascular endothelial growth factor–, fibroblast growth factor–, and BMP10-mediated vessel formation. The growth of B16 melanoma explants was also inhibited significantly by ALK1-Fc in this assay. Finally, ALK1-Fc treatment reduced tumor burden in mice receiving orthotopic grafts of MCF7 mammary adenocarcinoma cells. These data show the efficacy of chimeric ALK1-Fc proteins in mitigating vessel formation and support the view that ALK1-Fc is a powerful antiangiogenic agent capable of blocking vascularization. Mol Cancer Ther; 9(2); 379–

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1535-7163.mct-09-0650

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 155

Metadata

Authors
Mitchell, D., Pobre, E. G., Mulivor, A. W., Grinberg, A. V., Castonguay, R., Monnell, T. E., Solban, N., Ucran, J. A., Pearsall, R. S., Underwood, K. W., Seehra, J., & Kumar, R.
Venue
Molecular Cancer Therapeutics
Published
2010-02-01
Volume
9
Issue
2
Pages
379-388
ISSN
  • 1535-7163 (ISSN-L)
  • 1538-8514
OpenAlex
W2104603588
Cited by
155
References
0
FWCI
5.91
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: ALK1-Fc Inhibits Multiple Mediators of Angiogenesis and Suppresses Tumor Growth. https://app.cochat.ai/papers/10.1158/1535-7163.mct-09-0650
The paper
Mitchell, D., Pobre, E. G., Mulivor, A. W., Grinberg, A. V., Castonguay, R., Monnell, T. E., Solban, N., Ucran, J. A., Pearsall, R. S., Underwood, K. W., Seehra, J., & Kumar, R. (2010). ALK1-Fc Inhibits Multiple Mediators of Angiogenesis and Suppresses Tumor Growth. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-09-0650

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.